Neurogen deal

The remainder of the funding includes three optional payments of $3 million each, plus milestones that could total $34 million. The agreement is renewable up to three more years.

Schering-Plough will receive exclusive rights to all therapeutic modalities resulting from NRGN's dopamine discovery program, and rights to test certain compounds from NRGN's combinatorial chemistry program in selected Schering-Plough assays. ...